Oxidative and nitrosative stress and immune-inflammatory pathways in patients with myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS)

Current Neuropharmacology

Volumn 12, Issue 2, 2014, Pages 168-185

  Morris, Gerwyn ^a   Maes, Michael ^b,c  

^a Tir Na Nog   (United Kingdom)

^b CHULALONGKORN UNIVERSITY   (Thailand)

^c DEAKIN UNIVERSITY   (Australia)

Author keywords

Autoimmune; Chronic fatigue syndrome; Cytokines; Inflammation; Myalgic encephalomyelitis; Nitrosative stress; Oxidative

Indexed keywords

NITRIC OXIDE; OMEGA 6 FATTY ACID; PEROXYNITRITE; TOLL LIKE RECEPTOR;

ARTICLE; BACTERIAL TRANSLOCATION; BRAIN DISEASE; CHRONIC FATIGUE SYNDROME; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DNA MODIFICATION; ENERGY METABOLISM; ENERGY YIELD; HUMAN; IMMUNE RESPONSE; INNATE IMMUNITY; LIPID MEMBRANE; LIPID PEROXIDATION; MOLECULAR PATHOLOGY; NERVOUS SYSTEM INFLAMMATION; NITRATION; NITROSATIVE STRESS; NONHUMAN; OPPORTUNISTIC INFECTION; OXIDATIVE STRESS; PERFUSION; SIGNAL TRANSDUCTION; TOXICITY;

EID: 84896362511     PISSN: 1570159X     EISSN: 18756190     Source Type: Journal    
DOI: 10.2174/1570159X11666131120224653     Document Type: Article

References (311)

1. Morris, G.; Maes, M. A neuro-immune model of Myalgic Encephalomyelitis/Chronic fatigue syndrome. Metab. Brain Dis., [Epub ahead of print] 2012. PMID: 22718491.
2. Morris, G.; Anderson, G.; Galecki, P.; Berk, M.; Maes, M. A narrative review on the similarities and dissimilarities between myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and sickness behavior. BMC Med., 2013, 11, 64. http://dx.doi.org/10.1186/1741-7015-11-64
3. Maes, M.; Mihaylova, I.; De Ruyter, M. Lower serum zinc in Chronic Fatigue Syndrome (CFS): relationships to immune dysfunctions and relevance for the oxidative stress status in CFS. J. Affect. Disord., 2006, 90(2-3), 141-147. http://dx.doi.org/10.1016/j.jad.2005.11.002
4. Maes, M., Mihaylova, I., Kubera, M., Uytterhoeven, M., Vrydags, N., Bosmans, E. Coenzyme Q10 deficiency in Myalgic ncephalomyelitis/chronic fatigue syndrome (ME/CFS) is related to fatigue, autonomic and neurocognitive symptoms and is another risk factor explaining the early mortality in ME/CFS due to cardiovascular disorder. Neuro. Endocrinol. Lett., 2009, 30(4), 470-476. PMID: 20010505.
5. Maes, M., Twisk, F.N. Chronic fatigue syndrome: Harvey and Wessely's (bio)psychosocial model versus a bio(psychosocial) model based on inflammatory and oxidative and nitrosative stress pathways. BMC Med., 2010, 8, 35. http://dx.doi.org/10.1186/1741-7015-8-35
6. Maes, M.; Twisk, F.N.M.; Kubera, M.; Ringel, K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): Increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin. J. Affect. Disord., 2011, 136(3), 933-939. http://dx.doi.org/10.1016/j.jad.2011.09.004
7. Manuel Y., Keenoy, B.; Moorkens, G.; Vertommen, J.; De Leeuw, I. Antioxidant status and lipoprotein peroxidation in chronic fatigue syndrome. Life Sci., 2001, 68(17),2037-2049. http://dx.doi.org/10.1016/S0024-3205(01)01001-3
8. Vecchiet, J.; Cipollone, F.; Falasca, K.; Mezzetti, A.; Pizzigallo, E.; Bucciarelli, T.; De Laurentis, S.; Affaitati, G.; De Cesare, D.; Giamberardino, M.A. Relationship between musculoskeletal symptoms and blood markers of oxidative stress in patients with chronic fatigue syndrome. Neurosci. lett., 2003, 335(3), 151-154. http://dx.doi.org/10.1016/S0304-3940(02)01058-3
9. Smirnova, I.V.; Pall, M.L.; Elevated levels of protein carbonyls in sera of chronic fatigue syndrome patients. Mol. Cell. Biochem., 2003, 248(1-2), 93-95. DOI: 10.1023/A:1024176016962
10. Miwa, K.; Fujita, M. Increased oxidative stress suggested by low serum vitamin E concentrations in patients with chronic fatigue syndrome. Int. J. Cardiol., 2009, 136(2), 238-239. http://dx.doi.org/10.1016/j.ijcard.2008.04.051
11. Jason, L.; Sorenson, M.; Sebally, K.; Alkazemi, D.; Lerch, A.; Porter, N.; Kubow, S. Increased HDAC in association with decreased plasma cortisol in older adults with chronic fatigue syndrome. Brain Behav. Immun. 2011, 25(8), 1544-5417. http://dx.doi.org/10.1016/j.bbi.2011.04.007
12. Brkic, S.; Tomic, S.; Maric, D.; Novako V., Mikic, A.; Turkulov, V. Lipid peroxidation is elevated in female patients with chronic fatigue syndrome. Med. Sci. Monit., 2010, 16(12), CR628-CR632. ISSN: 15076164
13. Kennedy, G.; Spence, V.A.; McLaren, M.; Hill, A.; Underwood, C.; Belch, J.J. Oxidative stress levels are raised in chronic fatigue syndrome and are associated with clinical symptoms. Free Radic. Biol. Med., 2005, 39(5), 584-589. http://dx.doi.org/10.1016/j.freeradbiomed.2005.04.020
14. Manuel Y., Keenoy, B.; Moorkens, G.; Vertommen, J.; Noe, M.; Nève, J.; De Leeuw, I. Magnesium status and parameters of thestick oxidant-antioxidant balance in patients with chronic fatigue: effects of supplementation with magnesium. J. Am. Coll. Nutr., 2000, 19(3), 374-382. http://dx.doi.org/10.1080/07315724.2000.10718934
15. Richards, R.S.; Roberts, T.K.; McGregor, N.R.; Dunstan, R.H.; Butt, H.L. Blood parameters indicative of oxidative stress are associated with symptom expression in chronic fatigue syndrome. Redox Rep., 2000, 5(1), 35-41. PubMed ID: 10905542
16. Richards, R.S.; Wang, L., Jelinek, H. Erythrocyte oxidative damage in chronic fatigue syndrome. Arch. Med. Res., 2007, 38(1), 94-8. http://dx.doi.org/10.1016/j.arcmed.2006.06.008
17. Kurup, R.K.; Kurup, P.A. Isoprenoid pathway dysfunction in chronic fatigue syndrome. Acta. Neuropsychiatrica., 2003, 15(5), 266-273. http://dx.doi.org/10.1034/j.1601-5215.2003.00045.x
18. Miwa, K.; Fujita, M. Fluctuation of serum vitamin E (alpha-tocopherol) concentrations during exacerbation and remission phases in patients with chronic fatigue syndrome. Heart Vessels., 2010, 25(4), 319-323. http://dx.doi.org/10.1007/s00380-009-1206-6
19. Maes, M.; Mihaylova, I.; Kubera, M.; Bosmans, E. Not in the mind but in the cell: increased production of cyclo-oxygenase-2 and inducible NO synthase in chronic fatigue syndrome. Neuro. Endocrinol. Lett., 2007, 28(4), 463-469. PMID: 17693978
20. Maes, M.; Twisk, F.N.; Johnson, C. Myalgic Encephalomyelitis (ME), Chronic Fatigue Syndrome (CFS), and Chronic Fatigue (CF) are distinguished accurately: Results of supervised learning techniques applied on clinical and inflammatory data. Psychiatry Res., 2012, 200(2-3), 754-760. http://dx.doi.org/10.1016/j.psychres.2012.03.031
21. Jammes, Y.; Steinberg, J.G.; Mambrini, O.; Brégeon, F.; Delliaux, S. Chronic fatigue syndrome: assessment of increased oxidative stress and altered muscle excitability in response to incremental exercise. J. Intern. Med. 2005, 257(3), 299-310. http://dx.doi.org/10.1111/j.1365-2796.2005.01452.x
22. Jammes, Y.; Steinberg, J.G.; Delliaux, S.; Bregeon, F. Chronic fatigue syndrome combines increased exercise-induced oxidative stress and reduced cytokine and Hsp responses. J. Intern. Med. 2009, 266(2), 196-206. http://dx.doi.org/10.1111/j.1365-2796.2009.02079.x
23. Jammes, Y.; Steinberg, J.G.; Delliaux, S. Chronic fatigue syndrome: acute infection and history of physical activity affect resting levels and response to exercise of plasma oxidant/antioxidant status and heat shock proteins. J. Intern. Med., 2012, 272(1), 74-84. http://dx.doi.org/10.1111/j.1365-2796.2011.02488.x
24. Fulle, S.; Pietrangelo, T.; Mancinelli, R.; Saggini, R.; Fanò, G. Specific correlations between muscle oxidative stress and chronic fatigue syndrome: a working hypothesis. J. Muscle Res. Cell. Motil., 2007, 28(6), 355-362. http://dx.doi.org/10.1007/s10974-008-9128-y
25. Shungu, D.C.; Weiduschat, N.; Murrough, J.W.; Mao, X.; Pillemer, S.; Dyke, J.P.; Medow, M.S.; Natelson, B.H.; Stewart, J.M.; Mathew, SJ. Increased ventricular lactate in chronic fatigue syndrome. III. Relationships to cortical glutathione and clinical symptoms implicate oxidative stress in disorder pathophysiology. NMR Biomed., 2012, 25(9), 1073-1087. http://dx.doi.org/10.1002/nbm.2772
26. Geffard, M.; Bodet, D.; Martinet, Y.; Dabadie, M.P. Detection of the specific IgM and IgA circulating in sera of multiple sclerosis patients: interest and perspectives. Immunoanalyse & Biologie Specialisee., 2002, 17(5), 302-310. http://dx.doi.org/10.1016/S0923-2532(02)01214-0
27. Maes, M.; Twisk, F.N.; Kubera, M.; Ringel, K. Evidence for inflammation and activation of cell-mediated immunity in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS): increased interleukin-1, tumor necrosis factor-a, PMN-elastase, lysozyme and neopterin. J. Affect. Disord., 2012, 136(3), 933-939. http://dx.doi.org/10.1016/jjad.2011.09.004
28. Maes, M.; Twisk, F.N.; Ringel, K. Inflammatory and cell-mediated immune biomarkers in myalgic encephalomyelitis/chronic fatigue syndrome and depression: inflammatory markers are higher in myalgic encephalomyelitis/chronic fatigue syndrome than in depression. Psychother. Psychosom., 2012, 81(5), 286-95. http://dx.doi.org/10.1159/000336803
29. Lombardi, V.C.; Hagen, K.S.; Hunter, K.W.; Diamond, J.W.; Smith-Gagen, J.; Yang, W.; Mikovits, J.A. Xenotropic murine leukemia virus-related virus-associated chronic fatigue syndrome reveals a distinct inflammatory signature. In Vivo., 2011, 25(3), 307-314. PubMed ID: 21576403
30. Maher, K.J.; Klimas, N.G.; Fletcher, M.A. Chronic fatigue syndrome is associated with diminished intracellular perforin. Clin. Exp. Immunol, 2005,142, 505-511. DOI: 10.1111/j.1365-2249.2005.02935.x
31. Broderick, G.; Fuite, J.; Kreitz, A.; Vernon, S.D.; Klimas, N.; Fletcher, M.A. A formal analysis of cytokine networks in Chronic Fatigue Syndrome. Brain Behav. Immun., 2010, 24(7), 1209-1217. http://dx.doi.org/10.1016/j.bbi.2010.04.012
32. Vermeulen, R.C.W.; Kurk, R.M.; Visser, F.C.; Sluiter, W.; Scholte, H.R. Patients with chronic fatigue syndrome performed worse than controls in a controlled repeated exercise study despite a normal oxidative phosphorylation capacity. J. Transl. Med., 2010, 8, 93. http://dx.doi.org/10.1186/1479-5876-8-93
33. Myhill, S.; Booth, N.E.; McLaren-Howard, J. Chronic fatigue syndrome and mitochondrial dysfunction. Int. J. Clin. Exp. Med., 2009, 2(1), 1-16. ISSN: 19405901
34. Booth, N.E.; Myhill, S.; McLaren-Howard, J. Mitochondrial dysfunction and the pathophysiology of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). Int. J. Clin. Exp. Med., 2012, 5(3), 208-20. PMID: 22837795.
35. Behan, W.M.; More, I.A.; Behan, P.O. Mitochondrial Abnormalities in the Postviral Fatigue Syndrome. Ada. Neuropathologica, 1991, 83(1), 61-65. http://dx.doi.org/10.1007/BF00294431
36. Plioplys, A.V.; Plioplys, S. Electron-microscopic Investigation of Muscle Mitochondria in Chronic Fatigue Syndrome. Neuro-psychobiology. 1995, 32(4), 175-181. http://dx.doi.org/10.1159/000119233
37. Arnold, D.L.; Bore, P.J.; Radda, G.K.; Styles, P.; Taylor, DJ. Excessive intracellular acidosis of skeletal muscle on exercise in a patient with a post-viral exhaustion/fatigue syndrome. Lancet., 1984,1, 1367-1369. PMID: 6145831
38. Lane, R.J.; Barrett, M.C.; Taylor, DJ.; Kemp, G.J.; Lodi, R. Heterogeneity in Chronic Fatigue Syndrome: Evidence from Magnetic Resonance Spectroscopy of Muscle. Neuromuscul Disord., 1998, 5(3-4), 204-209. http://dx.doi.org/10.1016/S0960-8966(98)00021-2
39. Paul, L.; Wood, L.; Behan, W.M.; Maclaren, W.M. Demonstration of Delayed Recovery from Fatiguing Exercise in Chronic Fatigue Syndrome. Eur. J. Neurol, 1999, 6(1), 63-69. http://dx.doi.org/10.1046/j.1468-1331.1999.610063.x
40. Lane, R.J.M.; Barrett, M.C.; Woodrow, D.; Moss, J.; Fletcher, R.; Archard, L.C. Muscle Fibre Characteristics and Lactate Responses to Exercise in Chronic Fatigue Syndrome. J. Neurol. Neurosurg. Psychiatry, 1998, 64 (3), 362-367. http://dx.doi.org/10.1136/jnnp.64.3.362
41. Allen, D.G.; Lamb, G.D.; Westerbland, H. Skeletal Muscle Fatigue: Cellular Mechanisms. Physiol. Rev., 2008, 88(1), 287-332. http://dx.doi.org/10.1152/physrev.00015.2007
42. Adam-Vizi, V.; Chinopoulos, C. Bioenergetics and the Formation of Mitochondrial Reactive Oxygen Species. Trends Pharmacol. Sci., 2006, 27(12), 639-645. http://dx.doi.org/10.1016/j.tips.2006.10.005
43. Cadenas, E.; Davies, K.J.; Mitochondrial free radical generation, oxidative stress, and aging. Free Radic. Biol. Med., 2000, 29(3-4), 222-230. http://dx.doi.org/10.1016/S0891-5849(00)00317-8
44. Smith, R.; Murphy, M. Animal and Human Studies with the Mitochondrial-targeted Antioxidant MitoQ. Annals. N.Y. Acad. Sci. 2010, 1201, 96-103. http://dx.doi.org/10.1111/j.1749-6632.2010.05627.x
45. White, P.D.; Goldsmith, K.A.; Johnson, A.L.; Potts, L.; Walwyn, R.; DeCesare, J.C.; Baber, H.L.; Burgess, M.; Clark, L.V.; Cox, D.L.; Bavinton, J.; Angus, B.J.; Murphy, G.; Murphy, M.; O'Dowd, H.; Wilks, D.; McCrone, P.; Chalder, T.; Sharpe, M. PACE trial management group. 2011. Comparison of adaptive pacing therapy, cognitive behaviour therapy, graded exercise therapy, and specialist medical care for chronic fatigue syndrome (PACE): a randomised trial. Lancet. 2011, 377(9768), 823-836. http://dx.doi.org/10.1016/S0140-6736(11)60096-2
46. Twisk, F.N.; Maes, M. A review on cognitive behavorial therapy (CBT) and graded exercise therapy (GET) in myalgic encephalomyelitis (ME)/chronic fatigue syndrome (CFS): CBT/GET is not only ineffective and not evidence-based, but also potentially harmful for many patients with ME/CFS. Neuro. Endocrinol. Lett., 2009, 30(3), 284-299.
47. Kindlon, T. Reporting of Harms Associated with Graded Exercise Therapy and Cognitive Behavioural Therapy in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Bull. IACFS/ME., 2011, 19(2), 59-111.
48. Wong, R.; Lopaschuk, G.; Zhu, G.; Walker, D.; Catellier, D.; Burton, D.; Teo, K.; Collins-Nakai, R.; Montague, T. Skeletal muscle metabolism in the chronic fatigue syndrome. In vivo assessment by 31P nuclear magnetic resonance spectroscopy. Chest., 1992, 102(6), 1716-1722. PubMed ID: 1446478
49. Mathew, S.J.; Mao, X.; Keegan, K.A.; Levine, S.M.; Smith, E.L.; Heier, L.A.; Otcheretko, V.; Coplan, J.D.; Shungu, D.C. Ventricular cerebrospinal fluid lactate is increased in chronic fatigue syndrome compared with generalized anxiety disorder: an in vivo 3.0 T (1)H MRS imaging study. NMR Biomed., 2009, 22(3), 251-258. http://dx.doi.org/10.1002/nbm.1315
50. Murrough, J.W.; Mao, X.; Collins, K.A.; Kelly, C.; Andrade, G.; Nestadt, P.; Levine, S.M.; Mathew, S.J.; Shungu, D.C. Increased ventricular lactate in chronic fatigue syndrome measured by 1H MRS imaging at 3.0 T. II: comparison with major depressive disorder. NMR Biomed., 2010, 23(6), 643-650. http://dx.doi.org/10.1002/nbm.1512
51. Nakatomi, Y.; Mizuno, K.; Ishii, A.; Wada, Y.; Tanaka, M.; Tazawa, S.; Onoe, K.; Fukuda, S.; Kawabe, J.; Takahashi, K.; Kataoka, Y.; Shiomi, S.; Yamaguti, K.; Inaba, M.; KuraFranktsune, H.; Watanabe, Y. Microglial activation in patients with Chronic Fatigue Syndrome: a Positron Emission Tomography study with [11C]PK11195. Neurosci. Res., 2011. 71, issue (September 2011), p. e200. DOI: 10.1016/j.neures.2011.07.862
52. Barnden, L.R.; Crouch, B.; Kwiatek, R.; Burnet, R.; Mernone, A.; Chryssidis, S.; Scroop, G.; Del Fante, P. A brain MRI study of chronic fatigue syndrome: evidence of brainstem dysfunction and altered homeostasis. NMR Biomed., 2011, 24(10), 1302-1312. http://dx.doi.org/10.1002/nbm.1692
53. Puri, B.K.; Counsell S.J.; Zaman, R.; Main, J.; Collins, A.G.; Hajnal, J.V.; Davey, N.J. Relative increase in choline in the occipital cortex in chronic fatigue syndrome. Acta Psychiatr. Scand., 2002, 106(3), 224-226. http://dx.doi.org/10.1034/j.1600-0447.2002.01300.x
54. Ge, Y. Seeing is believing: in vivo evolution of multiple sclerosis pathology with magnetic resonance. Top. Magn. Reson. Imaging., 2006, 17(4), 295-306. http://dx.doi.org/10.1097/RMR.0b013e3180417d14
55. Chaudhuri, A.; Condon, B.; Gow, J.; Brennan, D.; Hadley, D. Proton magnetic resonance spectroscopy of basal ganglia in chronic fatigue syndrome. Brain Imaging. 2003, 14(2), 225-228. http://dx.doi.org/10.1097/00001756-200302100-00013
56. Tomoda, A.; Miike, T.; Yamada, E.; Honda, H.; Moroi, T.; Ogawa, M.; Ohtani, Y.; Morishita, S. Chronic fatigue syndrome in childhood. Brain Dev., 2000, 22(1), 60-64. http://dx.doi.org/10.1016/S0387-7604(99)00111-4
57. Narayana, P.A. Magnetic resonance spectroscopy in the monitoring of multiple sclerosis. J. Neuroimaging, 2005, 15(4 Suppl),46S-57S. http://dx.doi.org/10.1177/1051228405284200
58. Wehrl, H.F.; Schwab, J.; Hasenbach, K.; Reischl, G.; Tabatabai, G.; Quintanilla-Martinez, L.; Jiru, F.; Chughtai, K.; Kiss, A.; Cay, F.; Bukala, D.; Heeren, R.M.; Pichler, B.J.; Sauter, A.W. Multimodal elucidation of choline metabolism in a murine glioma model using magnetic resonance spectroscopy and 11C-choline positron emission tomography. Cancer Res., 2013, 73(5), 1470-1480. http://dx.doi.org/10.1158/0008-5472.CAN-12-2532
59. Clarke, C.E.; Lowry, M. Basal ganglia metabolite concentrations in idiopathic Parkinson's disease and multiple system atrophy measured by proton magnetic resonance spectroscopy. Eur. J. Neurol., 2000, 7(6), 661-665. http://dx.doi.org/10.1046/j.1468-1331.2000.00111.x
60. Satlin, A.; Bodick, N.; Offen, W.W.; Renshaw, P.F. Brain proton magnetic resonance spectroscopy (1H-MRS) in Alzheimer's disease: changes after treatment with xanomeline, an M1 selective cholinergic agonist. Am. J. Psychiatry, 1997, 154(10), 1459-1461. 9326834
61. Arnold, D.L.; Matthews, P.M.; Francis, G.S.; O'Connor, J.; Antel, J.P. Proton magnetic resonance spectroscopic imaging for metabolic characterization of demyelinating plaques. Ann. Neurol., 1992, 31(3), 235-241. http://dx.doi.org/10.1002/ana.410310302
62. Tartaglia, M.C.; Narayanan, S.; De Stefano, N.; Arnaoutelis, R.; Antel, S.B.; Francis, S.J.; Santos, A.C.; Lapierre, Y.; Arnold, D.L. Choline is increased in pre-lesional normal appearing white matter in multiple sclerosis. J. Neurol., 2002, 249(10), 1382-1390. http://dx.doi.org/10.1007/s00415-002-0846-6
63. Narayana, P.A.; Doyle, T.J.; Lai, D.; Wolinsky, J.S. Serial proton magnetic resonance spectroscopic imaging, contrast-enhanced magnetic resonance imaging, and quantitative lesion volumetry in multiple sclerosis. Ann. Neurol., 1998, 43(1), 56-71. http://dx.doi.org/10.1002/ana.410430112
64. Chow, S.L.; Rooney, Z.J.; Cleary, M.A.; Clayton, P.T.; Leonard, J.V. The significance of elevated CSF lactate. Arch. Dis. Child., 2005, 90(11), 1188-1189. http://dx.doi.org/10.1136/adc.2005.075317
65. Cui, H.; Kong, Y.; Zhang, H. Oxidative Stress, Mitochondrial Dysfunction, and Aging. J. Sign. Transd. 2012, 2012, 646354. PMID: 21977319
66. Schutzer, S.E.; Angel, T.E.; Liu, T.; Schepmoes, A.A.; Clauss, T.R., Adkins, J.N.; Camp, D.G.; Holland, B.K.; Bergquist, J.; Coyle, P.K.; Smith, R.D.; Fallon, B.A.; Natelson, B.H. Distinct Cerebrospinal Fluid Proteomes Differentiate Post-Treatment Lyme Disease from Chronic Fatigue Syndrome. PLoS ONE., 2011, 6(2), e17287. http://dx.doi.org/10.1371/journal.pone.0017287
67. Baraniuk, J.N.; Casado, B.; Maibach, H.; Clauw, D.J.; Pannell, L.K.; Hess, S.S. A Chronic Fatigue Syndrome - related proteome in human cerebrospinal fluid. BMC Neurol., 2005, 5, 22. DOI: 10.1186/1471-2377-5-22
68. Fang, H.; Xie, Q.; Boneva, R.; Fostel, J.; Perkins, R.; Tong, W. Gene expression profile exploration of a large dataset on chron. Pharmacogenomics., 2006, 7(3), 429-440. http://dx.doi.org/10.2217/14622416.7.3.429icfatiguesyndrome
69. Kaushik, N.; Fear, D.; Richards, S.C.; McDermott, C.R.; Nuwaysir, E.F.; Kellam, P.; Harrison, T.J.; Wilkinson, R.J.; Tyrrell, D.A.; Holgate, S.T.; Kerr, J.R. Gene expression in peripheral blood mononuclear cells from patients with chronic fatigue syndrome. J. Clin. Pathol., 2005, 58(8), 826-32. http://dx.doi.org/10.1136/jcp.2005.025718
70. Regland, B.; Andersson, M.; Abrahamsson, L.; Bagby, J.; Dyrehag, L.E.; Gottfries, C.G.; Increased concentrations of homocysteine in the cerebrospinal fluid in patients with fibromyalgia and chronic fatigue syndrome. Scand. J. Rheumatol., 1997, 26(4), 301-307. http://dx.doi.org/10.3109/03009749709105320
71. Tyagi, N.; Kumar, M.; Pushpakumar S.B.; Lominadze, D.; Moshal K.S.; Sen U.; Vacek T.P.; Tyagi S.C. Homocysteine attenuates blood brain barrier function by inducing oxidative stress and the junctional proteins. FASEB J., 2008, 22 (Meeting Abstract Supplement) 734.7
72. Tyagi, N.; Gillespie, W.; Vacek, J.C.; Sen, U.; Tyagi, S.C.; Lominadze, D. Activation of GABA-A receptor ameliorates homocysteine-induced MMP-9 activation by ERK pathway. J. Cell. Physiol., 2009, 220(1), 257-266. http://dx.doi.org/10.1002/jcp.21757
73. Obeid, R.; Herrmann, W. Mechanisms of homocysteine neuro-toxicity in neurodegenerative diseases with special reference to dementia. FEBS Lett., 2006, 580(13), 2994-3005. http://dx.doi.org/10.1016/j.febslet.2006.04.088
74. Chacón, I.J.; Molero, A.E.; Pino-Ramírez, G.; Luchsinger, J.A.; Lee, J.H.; Maestre G.E. Risk of dementia associated with elevated plasma homocysteine in a latin american population. Int. J. Alzheimers Dis. 2009, 23, 2009. PMID: 20798752
75. Boldyrev, A. Molecular mechanisms of homocysteine toxicity and possible protection against hyperhomocysteinemia. Recent Adv. Nutr. Prevent. Alzheimer's Dis., 2010, 127-143. ISSN 978-81-7895-470-7.
76. Nicolson, G.L.; Nicolson, N.L.; Haier, J. Chronic Fatigue Syndrome patients subsequently diagnosed with Lyme Disease Borrelia burgdorferi: evidence for mycoplasma species co-infections. JCFS., 2008, 14(4), 5-17. http://dx.doi.org/10.1080/10573320802091809
77. Seishima, M.; Mizutani, Y.; Shibuya, Y.; Arakawa, C. Chronic fatigue syndrome after human parvovirus B19 infection without persistent viremia. Dermatology, 2008, 216(4), 341-346. http://dx.doi.org/10.1159/000116723
78. Chia, J.K.; Chia, A.Y. Chronic fatigue syndrome is associated with chronic enterovirus infection of the stomach. J. Clin. Pathol., 2008, 61(1), 43-48. http://dx.doi.org/10.1136/jcp.2007.050054
79. Nicolson, G.L.; Gan, R.; Haier, J. Multiple co-infections (Mycoplasma, Chlamydia, human herpesvirus-6) in blood of chronic fatigue syndrome patients: association with signs and symptoms. APMIS, 2003, 111, 557-566. http://dx.doi.org/10.1034/j.1600-0463.2003.1110504.x
80. Maes, M.; Mihaylova, I.; Leunis, J.C. Increased serum IgA and IgM against LPS of enterobacteria in chronic fatigue syndrome (CFS): indication for the involvement of gram-negative entero-bacteria in the etiology of CFS and for the presence of an increased gut-intestinal permeability. J. Affect. Disord., 2007, 99(1-3), 237-240. http://dx.doi.org/10.1016/j.jad.2006.08.021
81. Maes, M.; Kubera, M.; Leunis, J.C. The gut-brain barrier in major depression: intestinal mucosal dysfunction with an increased translocation of LPS from gram negative enterobacteria (leaky gut) plays a role in the inflammatory pathophysiology of depression. Neuro-Endocrinol. Lett., 2008, 29(1), 117-124. PMID: 18283240
82. Maes, M.; Twisk, F.N.; Kubera, M.; Ringel, K.; Leunis, J.C.; Geffard, M. Increased IgA responses to the LPS of commensal bacteria is associated with inflammation and activation of cell-mediated immunity in chronic fatigue syndrome. J. Affect Disord., 2012, 136(3), 909-917. http://dx.doi.org/10.1016/j.jad.2011.09.010
83. Sheedy, J.R.; Wettenhall, R.E.; Scanlon, D.; Gooley, P.R.; Lewis, D.P.; McGregor, N.; Stapleton, D.I.; Butt, H.L.; De Meirleir, K.L. Increased d-lactic Acid intestinal bacteria in patients with chronic fatigue syndrome. In Vivo., 2009, 23,621-628. PubMed ID: 19567398
84. Evengard, B.; Nord, C.E.; Sullivan, A. Patients with chronic fatigue syndrome have higher numbers of anaerobic bacteria in the intestine compared to healthy subjects. Eur. Soc. Clin. Microbiol. Infect. Dis., 2007, 29, S340-S340. http://dx.doi.org/10.1016/S0924-8579(07)71079-8
85. Butt, H.L.; Dunstan, R.H.; McGregor, N.R.; Roberts, T.K.; Zerbes, M.; Klineberg, I.J. Alteration of the Bacterial Microbial Flora in Chronic Fatigue/Pain Patients. In: Clinical and scientific basis of chronic fatigue syndrome: from myth towards management International scientific meeting. Roberts, T.K., 1999, 95. https://getinfo.de/app/Alteration-of-the-Bacterial-Microbial-Flora-in/id/BLCP%3ACN033068530. ISBN: 0646369059
86. Rao, A.V.; Bested, A.C.; Beaulne, T.M.; Katzman, M.A.; Iorio, C.; Berardi, J.M.; Logan, A.C. A randomized, double-blind, placebo-controlled pilot study of a probiotic in emotional symptoms of chronic fatigue syndrome. Gut. Pathog., 2009, 1(1), 6. http://dx.doi.org/10.1186/1757-4749-1-6
87. Lin HC. 2004. Small intestinal bacterial overgrowth: a framework for understanding irritable bowel syndrome. JAMA, 292(7),852-8. DOI: 10.1001/jama.292.7.852
88. Deitch, E.A.; Sittig, K.; Li, M.; Berg, R.; Specian, R.D. Obstructive jaundice promotes bacterial translocation from the gut. Am. J. Surg. 1990, 159(1), 79-84. http://dx.doi.org/10.1016/S0002-9610(05)80610-5
89. Marchetti, G.; Tincati, C.; Silvestri, G. Microbial translocation in the pathogenesis of HIV infection and AIDS. Clin. Microbiol. Rev., 2013, 26(1), 2-18. http://dx.doi.org/10.1128/CMR.00050-12
90. Appay, V.; Sauce, D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J. Pathol., 2008, 214(2), 231-241. http://dx.doi.org/10.1002/path.2276
91. Brenchley, J.M.; Price, D.A.; Schacker, T.W.; Asher, T.E.; Silvestri, G.; Rao, S.; Kazzaz, Z.; Bornstein, E.; Lambotte, O.; Altmann, D.; Blazar, B.R.; Rodriguez, B.; Teixeira-Johnson, L.; Landay, A.; Martin, J.N.; Hecht, F.M.; Picker, L.J.; Lederman, M.M.; Deeks, S.G.; Douek, D.C. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med., 2006, 12(12), 1365-1371. http://dx.doi.org/10.1038/nm1511
92. Cardoso, F.L.; Kittel, A.; Veszelka, S.; Palmela, I.; Tóth, A.; Brites, D.; Deli, M.A.; Brito, M.A. Exposure to lipopolysaccharide and/or unconjugated bilirubin impair the integrity and function of brain microvascular endothelial cells. PLoS One., 2012, 7(5), e35919. http://dx.doi.org/10.1371/journal.pone.0035919
93. Block, M.L.; Zecca, L.; Hong, J.S. Microglia-mediated neuro-toxicity: uncovering the molecular mechanisms. Nat. Rev. Neurosci., 2007, 8(1), 57-69. http://dx.doi.org/10.1038/nrn2038
94. Lehnardt, S. Innate immunity and neuroinflammation in the CNS: the role of microglia in Toll-like receptor-mediated neuronal injury. Glia., 2010, 58(3), 253-263. DOI: 10.1002/glia.20928
95. Rock, R.B.; Gekker, G.; Hu, S.; Sheng, W.S.; Cheeran, M.; Lokensgard, J.R.; Peterson, P.K. Role of microglia in central nervous system infections. Clin. Microbiol. Rev. 2004, 17(4), 942-964. http://dx.doi.org/10.1128/CMR.17.4.942-964.2004
96. Ransohoff, R.M.; Brown, M.A. Innate immunity in the central nervous system. J. Clin. Invest., 2012, 122(4), 1164-1171. http://dx.doi.org/10.1172/JCI58644
97. Saijo, K.; Glass, C.K. Microglial cell origin and phenotypes in health and disease. Nat. Rev. Immunol., 2011, 11(11), 775-787. http://dx.doi.org/10.1038/nri3086
98. Gallego, C.; Golenbock, D.; Gomez, M.A.; Saravia, N.G. Toll-like receptors participate in macrophage activation and intracellular control of Leishmania (Viannia) panamensis. Infect. Immun., 2011, 79(7), 2871-2879. http://dx.doi.org/10.1128/IAI.01388-10
99. Lucas, K.; Maes, M. Role of the Toll Like Receptor (TLR) Radical Cycle in Chronic Inflammation: Possible Treatments Targeting the TLR4 Pathway. Mol. Neurobiol., 2003, 48(1), 190-204. http://dx.doi.org/10.1007/s12035-013-8425-7
100. Chakravarty, S.; Herkenham, M. Toll-like receptor 4 on nonhematopoietic cells sustains CNS inflammation during endotoxemia, independent of systemic cytokines. J. Neurosci., 2005, 25(7), 1788-1796. http://dx.doi.org/10.1523/JNEUROSCI.4268-04.2005
101. Lehnardt, S.; Schott, E.; Trimbuch, T.; Laubisch, D.; Krueger, C.; Wulczyn, G.; Nitsch, R.; Weber, J.R. A vicious cycle involving release of heat shock protein 60 from injured cells and activation of toll-like receptor 4 mediates neurodegeneration in the CNS. J. Neurosci., 2008, 28(10), 2320-2331. http://dx.doi.org/10.1523/JNEUROSCI.4760-07.2008
102. Mallard, C. 2012. Innate immune regulation by toll-like receptors in the brain. ISRN Neurol., 2012, 2012, 701950. PMID: 23097717
103. Gow, J.W.; Hagan, S.; Herzyk, P.; Cannon, C.; Behan, P.O.; Chaudhuri, A. A gene signature for post-infectious chronic fatigue syndrome. BMC Med. Genom, 2009, 2, 38. http://dx.doi.org/10.1186/1755-8794-2-38
104. Light, A.R.; White, A.T.; Hughen R.W.; Light K.C. Moderate exercise increases expression for sensory, adrenergic, and immune genes in chronic fatigue syndrome patients but not in normal subjects. J. Pain., 2009, 10 (10), 1099-1112. http://dx.doi.org/10.1016/j.jpain.2009.06.003
105. Rubartelli, A.; Lotze, M.T. Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol., 2007, 28(10), 429-436. http://dx.doi.org/10.1016/j.it.2007.08.004
106. Lotze, M.T.; Zeh, H.J.; Rubartelli, A.; Sparvero, L.J.; Amoscato, A.A.; Washburn, N.R.; Devera, M.E.; Liang, X.; Tör, M.; Billiar, T. The grateful dead: damage-associated molecular pattern molecules and reduction/oxidation regulate immunity. Immunol. Rev., 2007, 220, 60-81. http://dx.doi.org/10.1111/j.1600-065X.2007.00579.x
107. Uchida, K. Redox-derived damage-associated molecular patterns: Ligand function of lipid peroxidation adducts. Redox Biol., 2013, 1(1), 94-96. http://dx.doi.org/10.1016/j.redox.2012.12.005
108. Miller, Y.I.; Choi, S.H.; Wiesner, P.; Fang, L.; Harkewicz, R.; Hartvigsen, K.; Boullier, A.; Gonen, A.; Diehl, C.J.; Que, X.; Montano, E.; Shaw, P.X.; Tsimikas, S.; Binder, C.J.; Witztum, J.L. Oxidation-specific epitopes are danger-associated molecular patterns recognized by pattern recognition receptors of innate immunity. Circ. Res., 2011, 108(2), 235-248. http://dx.doi.org/10.1161/CIRCRESAHA.110.223875
109. Zhou, R.; Yazdi, A.S.; Menu, P.; Tschopp, J. A role for mitochondria in NLRP3 inflammasome activation. Nature, 2011, 469(7329), 221-5. http://dx.doi.org/10.1038/nature09663
110. Bonar, S.L., Brydges, S.D., Mueller, J.L., McGeough, M.D., Pena, C., Chen, D., Grimston, S.K., Hickman-Brecks, C.L., Ravindran, S., McAlinden, A., Novack, D.V., Kastner, D.L., Civitelli, R., Hoffman, H.M., Mbalaviele, G. Constitutively activated NLRP3 inflammasome causes inflammation and abnormal skeletal development in mice. PLoS One., 2012, 7(4), e35979. http://dx.doi.org/10.1371/journal.pone.0035979
111. Inoue, M.; Shinohara, M.L. NLRP3 Inflammasome and MS/EAE. Autoimmune Dis., 2013, 2013, 859145. PMID: 23365725
112. Miao, E.A.; Leaf, I.A.; Treuting, P.M.; Mao, D.P.; Dors, M.; Sarkar, A.; Warren, S.E.; Wewers, M.D.; Aderem, A. Caspase-1-induced pyroptosis is an innate immune effector mechanism against intracellular bacteria. Nat. Immunol., 2010, 11(12), 1136-1142. http://dx.doi.org/10.1038/ni.1960
113. Maes, M.; Mihaylova, I.; Leunis, J.C. In chronic fatigue syndrome, the decreased levels of omega-3 poly-unsaturated fatty acids are related to lowered serum zinc and defects in T cell activation. Neuro-Endocrinol. Lett., 2005, 26(6), 745-751. PubMed ID: 16380690
114. Tai, C.C., Ding, S.T. N-3 polyunsaturated fatty acids regulate lipid metabolism through several inflammation mediators: mechanisms and implications for obesity prevention. J. Nutr. Biochem., 2010, 21(5), 357-363. http://dx.doi.org/10.1016/j.jnutbio.2009.09.010
115. Behan, P.O.; Behan, W.M.; Horrobin, D. Effect of high doses of essential fatty acids on the postviral fatigue syndrome. Acta Neurol. Scand., 1990, 82(3), 209-216. http://dx.doi.org/10.1111/j.1600-0404.1990.tb04490.x
116. Puri, B.K., Holmes, J., Hamilton, G. Eicosapentaenoic acid-rich essential fatty acid supplementation in chronic fatigue syndrome associated with symptom remission and structural brain changes. Int. J. Clin. Pract., 2004, 58(3), 297-299. http://dx.doi.org/10.1111/j.1368-5031.2004.00073.x
117. Narayanan, A.; Popova, T.; Turell, M.; Kidd, J.; Chertow, J.; Popov, S.G.; Bailey, C.; Kashanchi, F.; Kehn-Hall, K. Alteration in superoxide dismutase 1 causes oxidative stress and p38 MAPK activation following RVFV infection. PLoS One, 2011, 6(5), e20354. http://dx.doi.org/10.1371/journal.pone.0020354
118. Song, Y.; Leonard, S.W.; Traber, M.G.; Ho, E. Zinc deficiency affects DNA damage, oxidative stress, antioxidant defenses, and DNA repair in rats. J. Nutr., 2009, 139(9), 1626-1631. http://dx.doi.org/10.3945/jn.109.106369
119. Kaur, S.; Nehru, B. Alteration in glutathione homeostasis and oxidative stress during the sequelae of trimethyltin syndrome in rat brain. Biol. Trace. Elem. Res., 2013, 153(1-3), 299-308. http://dx.doi.org/10.1007/s12011-013-9676-x
120. Belrose, J.C.; Xie, Y.F.; Gierszewski, L.J.; MacDonald, J.F.; Jackson, M.F. Loss of glutathione homeostasis associated with neuronal senescence facilitates TRPM2 channel activation in cultured hippocampal pyramidal neurons. Mol. Brain, 2012, 5, 11. http://dx.doi.org/10.1186/1756-6606-5-11
121. Federico, A.; Cardaioli, E.; Da Pozzo, P.; Formichi, P.; Gallus, G.N.; Radi, E. Mitochondria, oxidative stress and neurodegeneration. J. Neurol. Sci., 2012, 322 (1-2), 254-262. http://dx.doi.org/10.1016/j.jns.2012.05.030
122. Sofic, E.; Lange, K.W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett., 1992, 142(2), 128-130. http://dx.doi.org/10.1016/0304-3940(92)90355-B
123. Cristalli, D.O., Arnal, N., Marra FA, de Alaniz MJ, Marra CA. Peripheral markers in neurodegenerative patients and their first-degree relatives. J. Neurol. Set, 2012, 314(1-2), 48-56. http://dx.doi.org/10.1016/jjns.2011.11.001
124. Klepac, N.; Relja, M.; Klepac, R.; Hecimovic, S.; Babic, T.; Trkulja, V. Oxidative stress parameters in plasma of Huntington's disease patients, asymptomatic Huntington's disease gene carriers and healthy subjects: a cross-sectional study. J. Neurol, 2007, 254(12), 1676-1683. http://dx.doi.org/10.1007/s00415-007-0611-y
125. Babu, G.N.; Kumar, A.; Chandra, R.; Puri, S.K.; Singh, R.L.; Kalita, J.; Misra, U.K. Oxidant-antioxidant imbalance in the erythrocytes of sporadic amyotrophic lateral sclerosis patients correlates with the progression of disease. Neurochem. Int., 2008, 52(6), 1284-1289. http://dx.doi.org/10.1016/j.neuint.2008.01.009
126. Parathath, S.R.; Parathath, S.; Tsirka, S.E. Nitric oxide mediates neurodegeneration and breakdown of the blood-brain barrier in tPA-dependent excitotoxic injury in mice. J. Cell Sci. 2006, 119, 339-349. http://dx.doi.org/10.1242/jcs.02734
127. Lochhead, J.J.; McCaffrey, G.; Quigley, C.E.; Finch, J.; DeMarco, K.M.; Nametz, N.; Davis, T.P. Oxidative stress increases blood-brain barrier permeability and induces alterations in occludin during hypoxia-reoxygenation. J. Cereb. Blood Flow Metab., 2010, 30 (9), 1625-1636. http://dx.doi.org/10.1038/jcbfm.2010.29
128. Yu, L.C., Wang, J.T., Wei, S.C., Ni, Y.H. Host-microbial interactions and regulation of intestinal epithelial barrier function: From physiology to pathology. World J. Gastrointest. Pathophysiol, 2012, 3(1), 27-43. DOI: 10.4291/wjgp.v3.i1.27.
129. Han, X., Fink, M.P., Delude, R.L. Proinflammatory cytokines cause NO*-dependent and -independent changes in expression and localization of tight junction proteins in intestinal epithelial cells. Shock, 2003,19(3), 229-237. PMID: 12630522.
130. Fujinami, R.S.; Oldstone, M.B. Amino acid homology between the encephalitogenic site of myelin basic protein and virus: mechanism for autoimmunity. Science, 1985, 250(4729), 1043-1045. http://dx.doi.org/10.1126/science.2414848
131. Lang, H.L.E.; Jacobsen, H.; Ikemizu, S.; Andersson, C; Harlos, K.; Madsen, L.; Hjorth, P.; Sondergaard, L.; Svejgaard, A.; Wucherpfennig, K.; Stuart, D.I.; Bell, J.I.; Jones, E.Y.; Fugger, L. A functional and structural basis for TCR cross-reactivity in multiple sclerosis. Nat. Immunol, 2002, 3, 940-943. http://dx.doi.org/10.1038/ni835
132. Zajac, A.J.; Muller, D.; Pederson, K.; Frelinger, J.A.; Quinn, D.G. Natural killer cell activity in lymphocytic choriomeningitis virus-infected beta 2-microglobulin-deficient mice. Int. Immunol, 1995, 7, 1545-1556. http://dx.doi.org/10.1093/intimm/7.10.1545
133. Al-Sadi, R.; Ye, D.; Said, H.M.; Ma, T.Y. IL-1beta-induced increase in intestinal epithelial tight junction permeability is mediated by MEKK-1 activation of canonical NF-kappaB pathway. Am. J. PathoL, 2010, 777(5), 2310-2322. http://dx.doi.org/10.2353/ajpath.2010.100371
134. Maes, M.; Leunis, J.C. Normalization of leaky gut in chronic fatigue syndrome (CFS) is accompanied by a clinical improvement: effects of age, duration of illness and the translocation of LPS from gram-negative bacteria. Neuro-Endocrinol Lett., 2008, 29(6), 902-910. PMID: 19112401.
135. Wucherpfennig, K.W.; Ota, K.; Endo, N.; Seidman, J.G.; Rosenzweig, A.; Weiner, H.L.; Hafler, D.A. Shared human T cell receptor Vb usage to immunodominant regions of myelin basic protein. Science, 1990,248, 1016-1019. PMID: 1693015.
136. Ericsson, A.; Arias, C; Sawchenko, P.E. Evidence for an intra-medullary prostaglandin-dependent mechanism in the activation of stress-related neuroendocrine circuitry by intravenous interleukin-1. J. Neurosci., 1997, 77(18), 7166-7179. http://dx.doi.org/10.1111/j.1460-9568.2008.06296.x
137. Marty, V.; El Hachmane M.; Amédée, T. Dual modulation of synaptic transmission in the nucleus tractus solitarius by prostaglandin E2 synthesized downstream of IL-1beta. Eur. J. Neurosci., 2008, 27(12), 3132-3150. http://dx.doi.org/10.1016/S0306-4522(98)00368-6
138. Konsman, J.P.; Kelley, K.; Dantzer, R. Temporal and spatial relationships between lipopolysaccharide-induced expression of Fos, interleukin-1beta and inducible nitric oxide synthase in rat brain. Neuroscience, 1999, 89(2), 535-548.
139. Bechmann, I.; Galea, I.; Perry, V.H. What is the blood-brain barrier (not)? Trends Immunol., 2007, 28 (1), 5-11. http://dx.doi.org/10.1016/j.it.2006.11.007
140. Lacroix, S.; Feinstein, D.; Rivest, S. The bacterial endotoxin lipopolysaccharide has the ability to target the brain in upregulating its membrane CD14 receptor within specific cellular populations. Brain Pathol., 1998, 8(4), 625-640. PubMed ID: 9804372
141. Laflamme, N.; Lacroix, S.; Rivest, S. An essential role of interleukin-1beta in mediating NF-kappaB activity and COX-2 transcription in cells of the blood-brain barrier in response to a systemic and localized inflammation but not during endotoxemia. J. Neurosci., 1999, 19(24), 10923-10930. PMID: 10594073.
142. Ching, S.; Zhang, H.; Belevych, N.; He, L.; Lai, W.; Pu, X.A.; Jaeger, L.B.; Chen, Q.; Quan, N. Endothelial-specific knockdown of interleukin-1 (IL-1) type 1 receptor differentially alters CNS responses to IL-1 depending on its route of administration. J. Neurosci., 2007, 27(39), 10476-10486. http://dx.doi.org/10.1523/JNEUROSCI.3357-07.2007
143. Quan, N.; Banks, W.A. Brain-immune communication pathways. Brain Behav. Immun., 2007, 21(6), 727-735. http://dx.doi.org/10.1016/j.bbi.2007.05.005
144. Goehler, L.E., Erisir, A., Gaykema, R.P. Neural-immune interface in the rat area postrema. Neuroscience, 2006, 140(4), 1415-1434. http://dx.doi.org/10.1016/j.neuroscience.2006.03.048
145. Marvel, F.A.; Chen, C.C.; Badr, N.; Gaykema, R.P.; Goehler, L.E. Reversible inactivation of the dorsal vagal complex blocks lipopolysaccharide-induced social withdrawal and c-Fos expression in central autonomic nuclei. Brain Behav. Immun., 2004, 18(2), 123-134. http://dx.doi.org/10.1016/j.bbi.2003.09.004
146. Johnson, J.D.; Cortez, V.; Kennedy, S.L.; Foley, T.E.; Hanson, H.3rd.; Fleshner, M. Role of central beta-adrenergic receptors in regulating proinflammatory cytokine responses to a peripheral bacterial challenge. Brain Behav. Immun., 2008, 22(7), 1078-1086. http://dx.doi.org/10.1016/j.bbi.2008.03.007
147. Watkins, L.R.; Maier, S.F.; Goehler, L.E. Cytokine-to-brain communication: a review & analysis of alternative mechanisms. Life Sci., 1995, 57(11), 1011-1126. DOI: 10.1016/0024-3205(95) 02047-M
148. Tracey, K.J. The inflammatory reflex. Nature, 2002, 420(6917), 853-859. http://dx.doi.org/10.1038/nature01321
149. Watkins, L.R., Goehler, L.E., Relton, J.K., Tartaglia, N., Silbert, L., Martin, D., Maier, S.F. Blockade of interleukin-1 induced hyperthermia by subdiaphragmatic vagotomy: evidence for vagal mediation of immune-brain communication. Neurosci. Lett., 1995, 183(1-2), 27-31. http://dx.doi.org/10.1016/0304-3940(94)11105-R
150. Johnston, G.R.; Webster, N.R. Cytokines and the immuno-modulatory function of the vagus nerve. Br. J. Anaesth. 2009, 102(4), 453-462. http://dx.doi.org/10.1093/bja/aep037
151. Balasubramaniam, B.; Carter, D.A.; Mayer, E.J.; Dick, A.D. Microglia derived IL-6 suppresses neurosphere generation from adult human retinal cell suspensions. Exp. Eye Res., 2009, 89(5), 757-766. http://dx.doi.org/10.1016/j.exer.2009.06.019
152. Dheen, S.T.; Jun, Y.; Yan, Z.; Tay, S.S.; Ling, E.A. Retinoic acid inhibits expression of TNF-alpha and iNOS in activated rat microglia. Glia., 2005, 50(1), 21-31. http://dx.doi.org/10.1002/glia.20153
153. Bi, X.L.; Yang, J.Y.; Dong, Y.X.; Wang, J.M.; Cui, Y.H.; Ikeshima, T.; Zhao, Y.Q.; Wu, C.F. Resveratrol inhibits nitric oxide and TNF-alpha production by lipopolysaccharide-activated microglia. Int. Immunopharmacol., 2005, 5(1), 185-193. http://dx.doi.org/10.1016/j.intimp.2004.08.008
154. Moss, D.W.; Bates, T.E. Activation of murine microglial cell lines by lipopolysaccharide and interferon-gamma causes NO-mediated decreases in mitochondrial and cellular function. Eur. J. Neurosci., 2001, 13(3), 529-538. http://dx.doi.org/10.1046/j.1460-9568.2001.01418.x
155. Liu, B.; Gao, H.M.; Wang, J.Y.; Jeohn, G.H.; Cooper, C.L. Hong JS. Role of nitric oxide in inflammation-mediated neurodegeneration. Ann. N. Y. Acad. Sci., 2002, 962, 318-331. http://dx.doi.org/10.1111/j.1749-6632.2002.tb04077.x
156. Colton, C.A.; Gilbert, D.L. Production of superoxide anions by a CNS macrophage, the microglia. FEBS Lett., 1987, 223(2), 284-288. http://dx.doi.org/10.1016/0014-5793(87)80305-8
157. Mao, H.; Liu, B. Synergistic microglial reactive oxygen species generation induced by pesticides lindane and dieldrin. Neuroreport, 2008, 19(13), 1317-1320. http://dx.doi.org/10.1097/WNR.0b013e32830b3677
158. Pascual, O.; Ben, A. S.; Rostaing, P.; Triller, A.; Bessis, A. Microglia activation triggers astrocyte-mediated modulation of excitatory neurotransmission. Proc. Natl. Acad. Sci. U. S. A., 2012, 109(4), E197-E205. http://dx.doi.org/10.1073/pnas.1111098109
159. Colangelo, A.M.; Cirillo, G.; Lavitrano, M.L.; Alberghina, L.; Papa, M. Targeting reactive astrogliosis by novel biotechnological strategies. Biotechnol. Adv., 2012, 30 (1), 261-271. http://dx.doi.org/10.1016/j.biotechadv.2011.06.016
160. Bezzi, P.; Volterra, A. A neuron-glia signalling network in the active brain. Curr. Opin. Neurobiol., 2001, 11(3), 387-394. http://dx.doi.org/10.1016/S0959-4388(00)00223-3
161. Font-Nieves, M.; Sans-Fons, M.G.; Gorina, R.; Bonfill-Teixidor, E.; Salas-Pérdomo, A.; Márquez-Kisinousky, L.; Santalucia, T.; Planas, A.M. Induction of COX-2 enzyme and down-regulation of COX-1 expression by lipopolysaccharide (LPS) control prostaglandin E2 production in astrocytes. J. Biol. Chem., 2012, 287(9), 6454-6468. http://dx.doi.org/10.1074/jbc.M111.327874
162. Möller, T. Neuroinflammation in Huntington's disease. J. Neural. Transm., 2012, 117(8), 1001-1008. http://dx.doi.org/10.1007/s00702-010-0430-7
163. Graeber, M.B; Li, W.; Rodriguez, M.L. Role of microglia in CNS inflammation. FEBS Lett., 2011, 585(23), 3798-3805. http://dx.doi.org/10.1016/j.febslet.2011.08.033
164. Block, M.L.; Hong, J.S. Chronic microglial activation and progressive dopaminergic neurotoxicity. Biochem. Soc. Trans., 2007, 35(Pt 5), 1127-1132. DOI: 10.1042/BST0351127
165. Sofroniew, M.V.; Vinters, H.V. Astrocytes: biology and pathology. Acta. Neuropathol., 2010, 119(1), 7-35. http://dx.doi.org/10.1007/s00401-009-0619-8
166. Kuboyama, K.; Harada, H.; Tozaki-Saitoh, H.; Tsuda, M.; Ushijima, K.; Inoue, K. Astrocytic P2Y(1) receptor is involved in the regulation of cytokine/chemokine transcription and cerebral damage in a rat model of cerebral ischemia. J. Cereb. Blood Flow Metab., 2011, 31(9), 1930-1941. http://dx.doi.org/10.1038/jcbfm.2011.49
167. McGraw, J.; Hiebert, G.W.; Steeves, J.D. Modulating astrogliosis after neurotrauma. J. Neurosci. Res., 2001, 63 (2), 109-115. http://dx.doi.org/10.1002/1097-4547(20010115)63:2109::AID-JNR10023.0.CO;2-J
168. North, R.A.; Verkhratsky, A. Purinergic transmission in the central nervous system. Pflugers. Arch., 2006, 452(5), 479-485. http://dx.doi.org/10.1007/s00424-006-0060-y
169. Rodríguez, J.J.; Olabarria, M.; Chvatal, A.; Verkhratsky, A. Astroglia in dementia and Alzheimer's disease. Cell. Death Differ., 2009, 16(3), 378-385. http://dx.doi.org/10.1038/cdd.2008.172
170. Li, L.; Lundkvist, A.; Andersson, D.; Wilhelmsson, U.; Nagai, N.; Pardo, A.C.; Nodin, C.; Ståhlberg, A.; Aprico, K.; Larsson, K.; Yabe, T.; Moons, L.; Fotheringham, A.; Davies, I.; Carmeliet, P.; Schwartz, J.P.; Pekna, M.; Kubista, M.; Blomstrand, F.; Maragakis, N.; Nilsson, M.; Pekny, M. Protective role of reactive astrocytes in brain ischemia. J. Cereb. Blood Flow Metab., 2008, 28(3), 468-481. http://dx.doi.org/10.1038/sj.jcbfm.9600546
171. Adzemovic, M.Z.; Zeitelhofer, M.; Eriksson, U.; Olsson, T.; Nilsson, I. Imatinib ameliorates neuroinflammation in a rat model of multiple sclerosis by enhancing blood-brain barrier integrity and by modulating the peripheral immune response. PLoS One., 2013, 8(2), e56586. http://dx.doi.org/10.1371/journal.pone.0056586
172. Olajide, O.A.; Bhatia, H.S.; de Oliveira, A.C.; Wright, C.W.; Fiebich, B.L. Inhibition of Neuroinflammation in LPS-Activated Microglia by Cryptolepine. Evid Based Complement Alter. Med., 2013, 2013, 459723. DOI: 10.1155/2013/459723
173. Franke, H.; Verkhratsky, A.; Burnstock, G.; Illes, P. Patho-physiology of astroglial purinergic signalling. Purinergic Signal., 2012, 8 (3), 629-657. http://dx.doi.org/10.1007/s11302-012-9300-0
174. Philips, T.; Robberecht, W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol., 2011, 10(3), 253-63. http://dx.doi.org/10.1016/S1474-4422(11)70015-1
175. Hirsch, E.C.; Vyas, S.; Hunot, S. Neuroinflammation in Parkinson's disease. Parkinsonism Relat. Disord., 2012, 18 Suppl 1, S210-2. http://dx.doi.org/10.1016/S1353-8020(11)70065-7
176. Sekiyama, K.; Sugama, S.; Fujita, M.; Sekigawa, A.; Takamatsu, Y.; Waragai, M.; Takenouchi, T.; Hashimoto, M. Neuro- inflammation in Parkinson's Disease and Related Disorders: A Lesson from Genetically Manipulated Mouse Models of a-Synucleinopathies. Parkinsons Dis., 2012, 2012 (2012), ID 271732. PMID: 22550610
177. Krause, D.L.; Miiller, N. Neuroinflammation, microglia and implications for anti-inflammatory treatment in Alzheimer's disease. Int. J. Alzheimers Dis. 2010, 2010, 732806. DOI: 10.4061/2010/732806
178. Hensley, K. Neuroinflammation in Alzheimer's disease: mechanisms, pathologic consequences, and potential for therapeutic manipulation. J. Alzheimers Dis., 2010, 27(1), 1-14. DOI: 10.3233/JAD-2010-1414
179. Lewis, C.A.; Manning, J.; Rossi, F.; Krieger, C. The Neuro-inflammatory Response in ALS: The Roles of Microglia and T Cells. Neurol. Res. Int., 2012, 2012, 803701. http://dx.doi.org/10.1155/2012/803701
180. Frank-Cannon, T.C.; Alto, L.T.; McAlpine, F.E.; Tansey, M.G. Does neuroinflammation fan the flame in neurodegenerative diseases? Mol. Neurodegener., 2009, 4, 47. http://dx.doi.org/10.1186/1750-1326-4-47
181. Nataf, S. Neuroinflammation responses and neurodegeneration in multiple sclerosis. Rev. Neurol. (Paris)., 2009, 755(12), 1023-1028. http://dx.doi.Org/10.1016/j.neurol.2009.09.012
182. Agius, L.M. Neuroinflammation as the proximate cause of signature pathogenic pattern progression in amyotrophic lateral sclerosis, AIDS, and multiple sclerosis. Pathol. Res. Int., 2012, 2012, 169270. DOI: 10.1155/2012/169270
183. Pacher, P.; Beckman, J.S.; Liaudet, L. Nitric oxide and peroxynitrite in health and disease. Physiol. Rev., 2007, 87(1), 315-424. http://dx.doi.Org/10.l 152/physrev.00029.2006
184. Iadecola, C; Zhang, F.; Xu, S.; Casey, R.; Ross, M.E. Inducible nitric oxide synthase gene expression in brain following cerebral ischemia. J. Cereb. Blood Flow Metab., 1995, 75(3), 378-384. http://dx.doi.org/10.1038/jcbfrn.1995.47
185. Yu, Z.; Kone, B.C. Hypermethylation of the inducible nitric-oxide synthase gene promoter inhibits its transcription. J. Biol. Chem., 2004, 279(45), 46954-46961. http://dx.doi.org/10.1074/jbc. M407192200
186. Prast, H.; Tran, M.H.; Fischer, H.; Philippu, A. Nitric oxide-induced release of acetylcholine in the nucleus accumbens: role of cyclic GMP, glutamate, and GABA. J. Neurochem., 1998, 71(1), 266-273. http://dx.doi.Org/10.1046/j.1471-4159.1998.71010266.x
187. Getting, S.J.; Segieth, J.; Ahmad, S.; Biggs, OS.; Whitton, P.S. Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo. Brain Res., 1996, 777(1-2), 196-199. http://dx.doi.org/10.1016/0006-8993(96)00127-8
188. Boulton, C.L.; Southam, E.; Garthwaite, J. Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase. Neurosci., 1995, 69(3), 699-703. http://dx.doi.org/10.1016/0306-4522(95)00349-N
189. Schuman, E.M.; Madison, D.V. A requirement for the intercellular messenger nitric oxide in long-term potentiation. Science., 1991, 254(5037), 1503-1506. http://dx.doi.org/10.1126/science.1720572
190. Sequeira, S.M.; Ambrósio, A.F.; Malva, J.O.; Carvalho, A.P.; Carvalho, CM. Modulation of glutamate release from rat hippocampal synaptosomes by nitric oxide. Nitric Oxide., 1997, 7(4), 315-329. http://dx.doi.org/10.1006/niox.1997.0144
191. Feldman, S.; Weidenfeld, J. Involvement of endogeneous glutamate in the stimulatory effect of norepinephrine and serotonin on the hypothalamo-pituitary-adrenocortical axis. Neuroendocrinology., 2004, 79(1), 43-53. http://dx.doi.Org/10.l 159/000076044
192. Kolo, L.L.; Westfall, T.C.; Macarthur, H. Nitric oxide decreases the biological activity of norepinephrine resulting in altered vascular tone in the rat mesenteric arterial bed. Am. J. Physiol. Heart Circ. Physiol., 2004, 286(1), H296-H303. http://dx.doi.org/10.1152/ajpheart.00668.2003
193. Shelkovnikov S.; Merlic, C.A.; Gonick, H.C. Influence of nitric oxide donors and peroxynitrite on the contractile effect and concentration of norepinephrine. Life Sci., 2004, 74 (23), 2919-2928. http://dx.doi.Org/10.1016/j.lfs.2003.ll.006
194. Dawson, V.L.; Dawson, T.M.; London, E.D.; Bredt, D.S.; Snyder, S.H. Nitric oxide mediates glutamate neurotoxicity in primary cortical cultures. Proc. Natl. Acad. Sci. U. S. A., 1991, 88(4), 6368-6371. http://dx.doi.org/!0.1073/pnas.88.14.6368
195. Pryor, W.A.; Squadrito, G.L. The chemistry of peroxynitrite: a product from the reaction of nitric oxide with superoxide. Am. J. Physiol., 1995, 268(5 Pt 1), L699-L722. PubMed ID: 7762673
196. Szabó, C. The pathophysiological role of peroxynitrite in shock, inflammation, and ischemia-reperfusion injury. Shock., 1996, 6(2), 79-88. http://dx.doi.org/10.1097/00024382-199608000-00001
197. Nathan, C. Specificity of a third kind: reactive oxygen and nitrogen intermediates in cell signaling. J. Clin. Invest., 2003, 111(6), 769-778. http://dx.doi.org/10.1172/JCI200318174
198. Beckman, J.S. Ischaemic injury mediator. Nature, 1990, 345(6270), 27-28. http://dx.doi.org/10.1038/345027b0
199. Beckman, J.S.; Beckman, T.W.; Chen, J.; Marshall, P.A.; Freeman, B.A. Apparent hydroxyl radical production by peroxynitrite: implications for endothelial injury from nitric oxide and superoxide. Proc. Natl. Acad. Sci. U. S. A., 1990, 87(4), 1620-1624. http://dx.doi.org/10.1073/pnas.87.4.1620
200. Beckman, J.S.; Koppenol, W.H. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am. J. Physiol., 1996, 271(5 Pt 1), C1424-C1437. PubMed ID: 8944624
201. Denicola, A.; Souza, J.M.; Radi, R. Diffusion of peroxynitrite across erythrocyte membranes. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(7), 3566-3571. http://dx.doi.org/10.1073/pnas.95.7.3566
202. Aulak, K.S.; Miyagi, M.; Yan, L.; West, K.A.; Massillon, D.; Crabb, J.W.; Stuehr, D.J. Proteomic method identifies proteins nitrated in vivo during inflammatory challenge. Proc. Natl. Acad. Sci. U. S. A. 2001, 98(21), 12056-12061. http://dx.doi.org/10.1073/pnas.221269198
203. Gow, A.J.; Farkouh, C.R.; Munson, D.A.; Posencheg, M.A.; Ischiropoulos, H. Biological significance of nitric oxide-mediated protein modifications. Am. J. Physiol. Lung Cell. Mol. Physiol., 2004, 287(2), L262-L268. http://dx.doi.org/10.1152/ajplung.00295.2003
204. Kanski, J.; Behring, A.; Pelling, J.; Schöneich, C. Proteomic identification of 3-nitrotyrosine-containing rat cardiac proteins: effects of biological aging. Am. J. Physiol. Heart. Circ. Physiol., 2005, 288(1), H371-H381. http://dx.doi.org/10.1152/ajpheart.01030. 2003
205. Kanski, J.; Hong, S.J.; Schöneich, C. Proteomic analysis of protein nitration in aging skeletal muscle and identification of nitrotyrosine-containing sequences in vivo by nanoelectrospray ionization tandem mass spectrometry. J. Biol. Chem. 2005, 280(25), 24261-24266. http://dx.doi.org/10.1074/jbc.M501773200
206. Boccini, F.; Herold, S. Mechanistic studies of the oxidation of oxyhemoglobin by peroxynitrite. Biochemistry., 2004, 43(51), 16393-16404. http://dx.doi.org/10.1021/bi0482250
207. Herold, S.; Exner, M.; Boccini, F. The mechanism of the peroxynitrite-mediated oxidation of myoglobin in the absence and presence of carbon dioxide. Chem. Res. Toxicol., 2003, 16 (3), 390-402. http://dx.doi.org/10.1021/tx025595l
208. Thomson, L.; Trujillo, M.; Telleri, R.; Radi, R. Kinetics of cytochrome c2+ oxidation by peroxynitrite: implications for superoxide measurements in nitric oxide-producing biological systems. Arch. Biochem. Biophys., 1995, 319(2), 491-497.
209. Hühmer, A.F; Nishida, C.R.; Ortiz, de Montellano, P.R.; Schöneich, C. Inactivation of the inducible nitric oxide synthase by peroxynitrite. Chem. Res. Toxicol., 1997, 10(5), 618-626.
210. Castro, L.; Rodriguez, M.; Radi, R. Aconitase is readily inactivated by peroxynitrite, but not by its precursor, nitric oxide. J. Biol. Chem., 1994, 269(47), 29409-29415. PubMed ID: 7961920
211. Keyer, K.; Imlay, J.A. Inactivation of dehydratase [4Fe-4S] clusters and disruption of iron homeostasis upon cell exposure to peroxynitrite. J. Biol. Chem. 1997, 272(44), 27652-27659. http://dx.doi.org/10.1074/jbc.272.44.27652
212. Zou, M.H.; Cohen, R.; Ullrich, V. Peroxynitrite and vascular endothelial dysfunction in diabetes mellitus. Endothelium., 2004, 11(2), 89-97. http://dx.doi.org/10.1080/10623320490482619
213. Crow, J.P.; Beckman, J.S.; McCord, J.M. Sensitivity of the essential zinc-thiolate moiety of yeast alcohol dehydrogenase to hypochlorite and peroxynitrite. Biochemistry., 1995, 34 (11), 3544-3552. http://dx.doi.org/10.1021/bi00011a008
214. Radi, R.; Beckman, J.S.; Bush, K.M.; Freeman, B.A. Peroxynitrite oxidation of sulfhydryls. The cytotoxic potential of superoxide and nitric oxide. J. Biol. Chem., 1991, 266(7), 4244-4250. PubMed ID: 1847917
215. Pacher, P.; Obrosova, I.G.; Mabley, J.G.; Szabó C. Role of nitrosative stress and peroxynitrite in the pathogenesis of diabetic complications. Emerging new therapeutical strategies. Curr. Med. Chem., 2005, 12(3), 267-275. http://dx.doi.org/10.2174/0929867053363207
216. Rork, T.H.; Hadzimichalis, N.M.; Kappil, M.A.; Merrill, G.F. Acetaminophen attenuates peroxynitrite-activated matrix metalloproteinase-2-mediated troponin I cleavage in the isolated guinea pig myocardium. J. Mol. Cell. Cardiol, 2006, 40(4), 553-561. http://dx.doi.org/10.1016/j.yjmcc.2006.01.010
217. Wang, W.; Sawicki, G.; Schulz, R. Peroxynitrite-induced myocardial injury is mediated through matrix metalloproteinase-2. Cardiovasc. Res. 2002, 53(1), 165-174. http://dx.doi.org/10.1016/S0008-6363(01)00445-X
218. Gürsoy-Ozdemir, Y.; Can, A.; Dalkara, T. Reperfusion-induced oxidative/nitrative injury to neurovascular unit after focal cerebral ischemia. Stroke., 2004, 35(6), 1449-1453. http://dx.doi.org/10.1161/01.STR.0000126044.83777.f4
219. Ischiropoulos, H.; Zhu, L.; Chen, J.; Tsai, M.; Martin, J.C.; Smith, CD.; Beckman, J.S. Peroxynitrite-mediated tyrosine nitration catalyzed by superoxide dismutase. Arch. Biochem. Biophys., 1992, 298(2), 431-437. http://dx.doi.org/10.1016/0003-9861(92)90431-U
220. MacMillan-Crow, L.A.; Thompson, J.A. Tyrosine modifications and inactivation of active site manganese superoxide dismutase mutant (Y34F) by peroxynitrite. Arch. Biochem. Biophys., 1999, 55(1), 82-88. http://dx.doi.org/10.1006/abbi.1999.1202
221. Yamakura, F.; Taka, H.; Fujimura, T.; Murayama, K. Inactivation of human manganese-superoxide dismutase by peroxynitrite is caused by exclusive nitration of tyrosine 34 to 3-nitrotyrosine. J. Biol. Chem., 1998, 273(23), 14085-14089. http://dx.doi.org/10.1074/jbc.273.23.14085
222. Aykaç-Toker, G.; Bulgurcuoglu, S.; Koçak-Toker, N. Effect of peroxynitrite on glutaredoxin. Hum. Exp. Toxicol, 2001, 20(7), 373-376. http://dx.doi.org/10.1191/096032701680350578
223. Trujillo, M.; Folkes, L.; Bartesaghi, S.; Kalyanaraman, B.; Wardman, P.; Radi, R. Peroxynitrite-derived carbonate and nitrogen dioxide radicals readily react with lipoic and dihydrolipoic acid. Free Radic. Biol. Med., 2005, 39(2), 279-288. http://dx.doi.org/10.1016/j.freeradbiomed.2005.03.014
224. Cuzzocrea, S.; Zingarelli, B.; O'Connor, M.; Salzman, A.L.; Szabó, C. Effect of L-buthionine-(S,R)-sulphoximine, an inhibitor of gamma-glutamylcysteine synthetase on peroxynitrite- and endotoxic shock-induced vascular failure. Br. J. Pharmacol, 1998, 123(3), 525-537. DOI: 10.1038/sj.bjp.0701612
225. Arteel, G.E.; Briviba, K.; Sies, H. Protection against peroxynitrite. FEBS Lett, 1999, 445 (2-3), 226-230. http://dx.doi.org/10.1016/S0014-5793(99)00073-3
226. Cuzzocrea, S.; Costantino, G.; Mazzon, E.; Caputi, A.P. Protective effect of N-acetylcysteine on multiple organ failure induced by zymosan in the rat. Crit. Care Med., 1999, 27(8), 1524-1532. http://dx.doi.org/10.1097/00003246-199908000-00021
227. Jonnala, R.R.; Buccafusco, J.J. Inhibition of nerve growth factor signaling by peroxynitrite. J. Neurosci. Res., 2001, 55(1), 27-34.
228. http://dx.doi.org/10.1002/1097-4547(20010101)63: 127::AID-JNR43.3.CO;2-R
229. Good, P.F.; Werner, P.; Hsu, A.; Olanow, C.W.; Perl, D.P. Evidence of neuronal oxidative damage in Alzheimer's disease. Am. J. Pathol, 1996,149(1), 21-28. PMCID: PMC1865248
230. Smith, M.A.; Richey Harris, P.L.; Sayre, L.M.; Beckman, J.S.; Perry, G. Widespread peroxynitrite-mediated damage in Alzheimer's disease. J. Neurosci., 1997,17(8), 2653-2657. PMID: 9092586
231. Good, P.F.; Hsu, A.; Werner, P.; Perl, D.P.; Olanow, C.W. Protein nitration in Parkinson's disease. J. Neuropathol. Exp. Neurol, 1998, 57(4), 338-342. http://dx.doi.org/10.1097/00005072-199804000-00006
232. Cookson, M.R.; Shaw, P.J. Oxidative stress and motor neurone disease. Brain Pathol, 1999, 9(1), 165-186. http://dx.doi.org/10.1111/j.1750-3639.1999.tb00217.x
233. Schmidt, P.; Youhnovski, N.; Daiber, A.; Balan, A.; Arsic, M.; Bachschmid, M.; Przybylski, M.; Ullrich, V. Specific nitration at tyrosine 430 revealed by high resolution mass spectrometry as basis for redox regulation of bovine prostacyclin synthase. J. Biol. Chem., 2003, 278(15), 12813-12819. http://dx.doi.org/10.1074/jbc. M208080200
234. Birnboim, H.C.; Lemay, A.M.; Lam, D.K.; Goldstein, R.; Webb, J.R. Cutting edge: MHC class II-restricted peptides containing the inflammation-associated marker 3-nitrotyrosine evade central tolerance and elicit a robust cell-mediated immune response. J. Immunol., 2003, 171(2), 528-532. PMID:12847213
235. Ohmori, H.; Kanayama, N. Immunogenicity of an inflammation-associated product, tyrosine nitrated self-proteins. Autoimmun. Rev., 2005, 4(4), 224-229. http://dx.doi.org/10.1016/j.autrev.2004.11.011
236. Hsu, H.C.; Zhou, T.; Kim, H.; Barnes, S.; Yang, P.; Wu, Q.; Zhou, J.; Freeman, B.A.; Luo, M.; Mountz, J.D. Production of a novel class of polyreactive pathogenic autoantibodies in BXD2 mice causes glomerulonephritis and arthritis. Arthritis Rheum., 2006, 54(1), 343-355. http://dx.doi.org/10.1002/art.21550
237. Khan, F., Ali, R. Antibodies against nitric oxide damaged poly L-tyrosine and 3-nitrotyrosine levels in systemic lupus erythematosus. J. Biochem. Mol. Biol., 2006, 39 (2), 189-196. http://dx.doi.org/10.5483/BMBRep.2006.39.2.189
238. Radi, R.; Beckman, J.S.; Bush, K.M.; Freeman, B.A. Peroxynitrite-induced membrane lipid peroxidation: the cytotoxic potential of superoxide and nitric oxide. Arch. Biochem. Biophys., 1991, 288(2), 481-487. http://dx.doi.org/10.1016/0003-9861(91)90224-7
239. Shi, H.; Noguchi, N.; Xu, Y.; Niki, E. Formation of phospholipid hydroperoxides and its inhibition by alpha-tocopherol in rat brain synaptosomes induced by peroxynitrite. Biochem. Biophys. Res. Commun., 1999, 257(3), 651-656. http://dx.doi.org/10.1006/bbrc.1999.0434
240. Smith, K.J.; Kapoor, R.; Felts, P.A. Demyelination: the role of reactive oxygen and nitrogen species. Brain Pathol., 1999, 9(1), 69-92. http://dx.doi.org/10.1111/j.1750-3639.1999.tb00212.x
241. van der Veen, R.C.; Roberts, L.J. Contrasting roles for nitric oxide and peroxynitrite in the peroxidation of myelin lipids. J. Neuroimmunol., 1999, 95(1-2), 1-7. http://dx.doi.org/10.1016/S0165-5728(98)00239-2
242. Burney, S., Caulfield, J.L., Niles, J.C., Wishnok, J.S., Tannenbaum, S.R., 1999. The chemistry of DNA damage from nitric oxide and peroxynitrite. Mutat. Res., 424 (1-2), 37-49. http://dx.doi.org/10.1016/S0027-5107(99)00006-8
243. Niles, J.C.; Wishnok, J.S.; Tannenbaum, S.R. Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: structures and mechanisms of product formation. Nitric Oxide., 2006, 14(2), 109-121. http://dx.doi.org/10.1016/j.niox.2005.11.001
244. Yu, H.; Venkatarangan, L.; Wishnok, J.S.; Tannenbaum, S.R. Quantitation of four guanine oxidation products from reaction of DNA with varying doses of peroxynitrite. Chem. Res. Toxicol., 2005, 18(12), 1849-1857. http://dx.doi.org/10.1021/tx050146h
245. Buchczyk, D.P.; Grune, T.; Sies, H.; Klotz, L.O. Modifications of glyceraldehyde-3-phosphate dehydrogenase induced by increasing concentrations of peroxynitrite: early recognition by 20S proteasome. Biol. Chem., 2003, 384 (2), 237-241. DOI: 10.1515/BC.2003.026
246. Souza, J.M.; Radi, R. Glyceraldehyde-3-phosphate dehydrogenase inactivation by peroxynitrite. Arch. Biochem. Biophys., 1998, 360(2), 187-194. http://dx.doi.org/10.1006/abbi.1998.0932
247. Konorev, E.A.; Hogg, N.; Kalyanaraman, B. Rapid and irreversible inhibition of creatine kinase by peroxynitrite. FEBS Lett., 1998, 427(2), 171-174. http://dx.doi.org/10.1016/S0014-5793(98)00413-X
248. Brown, G.C.; Borutaite, V. Inhibition of mitochondrial respiratory complex I by nitric oxide, peroxynitrite and S-nitrosothiols. Biochim. Biophys. Acta., 2004, 1658(1-2), 44-49. http://dx.doi.org/10.1016/j.bbabio.2004.03.016
249. Bolaños, J.P.; Heales, S.J.; Land, J.M.; Clark, J.B. Effect of peroxynitrite on the mitochondrial respiratory chain: differential susceptibility of neurones and astrocytes in primary culture. J. Neurochem., 1995, 64(5), 1965-1972. http://dx.doi.org/10.1046/j.1471-4159.1995.64051965.x
250. Pearce, L.L.; Kanai, A.J.; Epperly, M.W.; Peterson, J. Nitrosative stress results in irreversible inhibition of purified mitochondrial complexes I and III without modification of cofactors. Nitric Oxide., 2005, 13(4), 254-263. http://dx.doi.org/10.1016/j.niox.2005.07.010
251. Radi, R.; Cassina, A.; Hodara, R. Nitric oxide and peroxynitrite interactions with mitochondria. Biol. Chem., 2002, 383 (3-4), 401-409. http://dx.doi.org/10.1515/BC.2002.044
252. Radi, R., Cassina, A., Hodara, R., Quijano, C., Castro, L. Peroxynitrite reactions and formation in mitochondria. Free Radic. Biol. Med., 2002b, 33 (11), 1451-1464. http://dx.doi.org/10.1016/S0891-5849(02)01111-5
253. Lopez, C.J.; Qayyum, I.; Mishra, O.P.; Delivoria-Papadopoulos, M. Effect of nitration on protein tyrosine phosphatase and protein phosphatase activity in neuronal cell membranes of newborn piglets. Neurosci. Lett., 2005, 0(2), 78-81. http://dx.doi.org/10.1016/j.neulet.2005.04.089
254. Takakura, K.; Beckman, J.S.; MacMillan-Crow, L.A.; Crow, J.P. Rapid and irreversible inactivation of protein tyrosine phosphatases PTP1B, CD45, and LAR by peroxynitrite. Arch. Biochem. Biophys., 1999, 369(2), 197-207. http://dx.doi.org/10.1006/abbi.1999.1374
255. Cassina, A.M.; Hodara, R.; Souza, J.M.; Thomson, L.; Castro, L.; Ischiropoulos, H.; Freeman, B.A.; Radi, R. Cytochrome c nitration by peroxynitrite. J. Biol. Chem., 2000, 275(28), 21409-21415. http://dx.doi.org/10.1074/jbc.M909978199
256. Jang, B.; Han, S. Biochemical properties of cytochrome c nitrated by peroxynitrite. Biochimie., 2006, 88(1), 53-58. http://dx.doi.org/10.1016/j.biochi.2005.06.016
257. Han, D.; Canali, R.; Garcia, J.; Aguilera, R.; Gallaher, T.K.; Cadenas, E. Sites and mechanisms of aconitase inactivation by peroxynitrite: modulation by citrate and glutathione. Biochemistry., 2005, 44(36), 11986-11996. http://dx.doi.org/10.1021/bi0509393
258. Forsmark-Andrée, P.; Persson, B.; Radi, R.; Dallner, G.; Ernster, L. Oxidative modification of nicotinamide nucleotide transhydrogenase in submitochondrial particles: effect of endogenous ubiquinol. Arch. Biochem. Biophys., 1996, 336(1), 113-120. http://dx.doi.org/10.1006/abbi.1996.0538
259. Scarlett, J.L.; Packer, M.A.; Porteous, C.M.; Murphy, M.P. Alterations to glutathione and nicotinamide nucleotides during the mitochondrial permeability transition induced by peroxynitrite. Biochem. Pharmacol., 1996, 52(7), 1047-1055. http://dx.doi.org/10.1016/0006-2952(96)99426-5
260. Vieira, H.L.; Belzacq, A.S.; Haouzi, D.; Bernassola, F.; Cohen, I.; Jacotot, E.; Ferri, K.F.; El Hamel, C.; Bartle, L.M.; Melino, G.; Brenner, C.; Goldmacher, V.; Kroemer, G. The adenine nucleotide translocator: a target of nitric oxide, peroxynitrite, and 4-hydroxynonenal. Oncogene., 2001, 20(32), 4305-4316. http://dx.doi.org/10.1038/sj.onc.1204575
261. Szabó, C.; Zingarelli, B.; O'Connor, M.; Salzman, A.L. DNA strand breakage, activation of poly (ADP-ribose) synthetase, and cellular energy depletion are involved in the cytotoxicity of macrophages and smooth muscle cells exposed to peroxynitrite. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(5), 1753-1758. http://dx.doi.org/10.1073/pnas.93.5.1753
262. Liaudet, L. Poly(adenosine 5'-diphosphate) ribose polymerase activation as a cause of metabolic dysfunction in critical illness. Curr. Opin. Clin. Nutr. Metab. Care, 2002, 5(2), 175-184. PubMed ID: 11844985
263. Liaudet, L.; Szabó, G.; Szabó, C. Oxidative stress and regional ischemia-reperfusion injury: the peroxynitrite-poly(ADP-ribose) polymerase connection. Coron. Artery Dis., 2003, 14 (2), 115-122. http://dx.doi.org/10.1097/00019501-200304000-00004
264. Szabó, C. Multiple pathways of peroxynitrite cytotoxicity. Toxicol. Lett., 2003, 140-141, 105-112. http://dx.doi.org/10.1016/S0378-4274(02)00507-6
265. Ha, H.C.; Snyder, S.H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(24), 13978-13982. http://dx.doi.org/10.1073/pnas.96.24.13978
266. Liaudet, L.; Oddo, M. Role of poly(adenosine diphosphate-ribose) polymerase 1 in septic peritonitis. Curr. Opin. Crit. Care, 2003, 9(2), 152-158. http://dx.doi.org/10.1097/00075198-200304000-00012
267. Griendling, K.K.; Sorescu, D.; Ushio-Fukai, M. NAD(P)H oxidase: role in cardiovascular biology and disease. Circ. Res., 2000, 86(5), 494-501. http://dx.doi.org/10.1161/01.RES.86.5.494
268. Ohtsu, H.; Frank, G.D.; Utsunomiya, H.; Eguchi, S. Redox-dependent protein kinase regulation by angiotensin II: mechanistic insights and its pathophysiology. Antioxid. Redox. Signal., 2005, 7(9-10), 1315-1326. http://dx.doi.org/10.1089/ars.2005.7.1315
269. Paravicini, T.M.; Touyz, R.M. Redox signaling in hypertension. Cardiovasc. Res., 2006, 71(2), 247-258. http://dx.doi.org/10.1016/j.cardiores.2006.05.001
270. Tonks, N.K. Protein tyrosine phosphatases: from genes, to function, to disease. Nat. Rev. Mol. Cell. Biol., 2006, 7(11), 833-846. http://dx.doi.org/10.1038/nrm2039
271. Mallozzi, C.; Di Stasi, A.M.; Minetti, M. Peroxynitrite modulates tyrosine-dependent signal transduction pathway of human erythrocyte band 3. FASEB J., 1997, 11(14), 1281-1290. PubMed ID: 9409547
272. Gow, A.J.; Duran, D.; Malcolm, S.; Ischiropoulos, H. Effects of peroxynitrite-induced protein modifications on tyrosine phosphorylation and degradation. FEBS Lett., 1996, 385(1-2), 63-66.
273. Kong, S.K.; Yim, M.B.; Stadtman, E.R.; Chock, P.B. Peroxynitrite disables the tyrosine phosphorylation regulatory mechanism: Lymphocyte-specific tyrosine kinase fails to phosphorylate nitrated cdc2(6-20)NH2 peptidDi Stasi e. Proc. Natl. Acad. Sci. U. S. A., 1996, 93(8), 3377-3382.
274. Brito, C.; Naviliat, M.; Tiscornia, A.C.; Vuillier, F.; Gualco, G.; Dighiero, G.; Radi, R.; Cayota, A.M. Peroxynitrite inhibits T lymphocyte activation and proliferation by promoting impairment of tyrosine phosphorylation and peroxynitrite-driven apoptotic death. J. Immunol., 1999, 162(6), 3356-3366. PubMed ID: 10092790
275. Maccaglia, A.; Mallozzi, C.; Minetti, M. Differential effects of quercetin and resveratrol on Band 3 tyrosine phosphorylation signalling of red blood cells. Biochem. Biophys. Res. Commun., 2003, 305(3), 541-547. http://dx.doi.org/10.1016/S0006-291X(03)00762-9
276. Di Stasi, A.M.; Mallozzi, C.; Macchia, G.; Petrucci, T.C.; Minetti, M. Peroxynitrite induces tryosine nitration and modulates tyrosine phosphorylation of synaptic proteins. J. Neurochem., 1999, 73(2), 727-735. http://dx.doi.org/10.1046/j.1471-4159.1999.0730727.x
277. Li, X.; De Sarno, P.; Song, L.; Beckman, J.S.; Jope, R.S. Peroxynitrite modulates tyrosine phosphorylation and phosphoinositide signalling in human neuroblastoma SH-SY5Y cells: attenuated effects in human 1321N1 astrocytoma cells. Biochem. J., 1998, 331(Pt 2), 599-606. PubMed ID: 9531503
278. Dong, C.; Davis, R.J.; Flavell, R.A. MAP kinases in the immune response. Annu. Rev. Immunol., 2001, 20, 55-72. http://dx.doi.org/10.1146/annurev.immunol.20.091301.131133
279. Kang, K.W.; Choi, S.H.; Kim, S.G. Peroxynitrite activates NF-E2-related factor 2/antioxidant response element through the pathway of phosphatidylinositol 3-kinase: the role of nitric oxide synthase in rat glutathione S-transferase A2 induction. Nitric Oxide., 2002, 7(4), 244-253. http://dx.doi.org/10.1016/S1089-8603(02)00117-9
280. Qi, M.; Elion, E.A. MAP kinase pathways. J. Cell. Sci., 2005, 118(Pt 16), 3569-3572. http://dx.doi.org/10.1242/jcs.02470
281. Andreone, T.L.; O'Connor, M.; Denenberg, A.; Hake, P.W.; Zingarelli, B. Poly(ADP-ribose) polymerase-1 regulates activation of activator protein-1 in murine fibroblasts. J. Immunol., 2003, 170(4), 2113-2120. PubMed ID: 12574383
282. Go, Y.M.; Patel, R.P.; Maland, M.C.; Park, H.; Beckman, J.S.; Darley-Usmar, V.M.; Jo, H. Evidence for peroxynitrite as a signaling molecule in flow-dependent activation of c-Jun NH(2)-terminal kinase. Am. J. Physiol., 1999, 277(4 Pt 2), H1647-H1653. PubMed ID: 10516206
283. Jope, R.S.; Zhang, L.; Song, L. Peroxynitrite modulates the activation of p38 and extracellular regulated kinases in PC12 cells. Arch. Biochem. Biophys., 2000, 376(2), 365-370. http://dx.doi.org/10.1006/abbi.2000.1728
284. Kaji, T.; Kaieda, I.; Hisatsune, T.; Kaminogawa, S. 3-Morpholinosydnonimine hydrochloride induces p53-dependent apoptosis in murine primary neural cells: a critical role for p21(ras)-MAPK-p19(ARF) pathway. Nitric Oxide, 2002, 6(2), 125-134. DOI: 10.1006/niox.2001.0389
285. Zouki, C.; Zhang, S.L.; Chan, J.S.; Filep, J.G. Peroxynitrite induces integrin-dependent adhesion of human neutrophils to endothelial cells via activation of the Raf-1/MEK/Erk pathway. FASEB J., 2001, 15(1), 25-27. PubMed ID: 11099490
286. Mallozzi, C.; Di Stasi, A.M.; Minetti, M. Activation of src tyrosine kinases by peroxynitrite. FEBS Lett., 1999, 456(1), 201-206. http://dx.doi.org/10.1016/S0014-5793(99)00945-X
287. Mallozzi, C.; Di Stasi, M.A.; Minetti, M. Peroxynitrite-dependent activation of src tyrosine kinases lyn and hck in erythrocytes is under mechanistically different pathways of redox control. Free Radic. Biol. Med., 2001, 30(10), 1108-1117. http://dx.doi.org/10.1016/S0891-5849(01)00509-3
288. Mallozzi, C.; De Franceschi, L.; Brugnara, C.; Di Stasi, A.M. Protein phosphatase 1alpha is tyrosine-phosphorylated and inactivated by peroxynitrite in erythrocytes through the src family kinase fgr. Free Radic. Biol. Med., 2005, 38(12), 1625-1636. http://dx.doi.org/10.1016/j.freeradbiomed.2005.02.021
289. Hainaut, P.; Milner, J. Redox modulation of p53 conformation and sequence-specific DNA binding in vitro. Cancer Res., 1993, 53(19), 4469-4473. PMID: 8402615.
290. Buizza, L.; Cenini, G.; Lanni, C.; Ferrari-Toninelli, G.; Prandelli, C.; Govoni, S.; Buoso, E.; Racchi, M.; Barcikowska, M.; Styczynska, M.; Szybinska, A.; Butterfield, D.A.; Memo, M.; Uberti, D. Conformational altered p53 as an early marker of oxidative stress in Alzheimer's disease. PLoS One., 2012, 7(1), e29789. http://dx.doi.org/10.1371/journal.pone.0029789
291. Buizza, L.; Prandelli, C.; Bonini, S.A.; Delbarba, A.; Cenini, G.; Lanni, C.; Buoso, E.; Racchi, M.; Govoni, S.; Memo, M.; Uberti, D. Conformational altered p53 affects neuronal function: relevance for the response to toxic insult and growth-associated protein 43 expression. Cell. Death Dis., 2013, 4, e484. http://dx.doi.org/10.1038/cddis.2013.13
292. Cobbs, C.S.; Whisenhunt, T.R.; Wesemann, D.R.; Harkins, L.E.; Van Meir, E.G.; Samanta, M. Inactivation of wild-type p53 protein function by reactive oxygen and nitrogen species in malignant glioma cells. Cancer Res., 2003, 63(24), 8670-8673. PMID: 14695179
293. Platt, D.H.; Bartoli, M.; El-Remessy, A.B.; Al-Shabrawey, M.; Lemtalsi, T.; Fulton, D.; Caldwell, R.B. Peroxynitrite increases VEGF expression in vascular endothelial cells via STAT3. Free Radic. Biol. Med., 2005, 39(10), 1353-1361. http://dx.doi.org/10.1016/j.freeradbiomed.2005.06.015
294. He, G.; Yu, G.Y.; Temkin, V.; Ogata, H.; Kuntzen, C.; Sakurai, T.; Sieghart, W.; Peck-Radosavljevic, M.; Leffert, H.L.; Karin, M. Hepatocyte IKKbeta/NF-kappaB inhibits tumor promotion and progression by preventing oxidative stress-driven STAT3 activation. Cancer Cell, 2010, 17(3), 286-297. http://dx.doi.org/10.1016/j.ccr.2009.12.048
295. Bartoli, M.; Platt, D.H.; Lemtalsi, T.; El Remessy, A.; Rojas, M.; Caldwell, R.W.; Caldwell, R.B. Molecular Mechanisms of Oxidative Stress-induced STAT3 Activation in Endothelial Cells. FASEB J., 2006, 20 (Meeting Abstract Supplement) A703.
296. Martindale, J.L.; Holbrook, N.J. Cellular response to oxidative stress: signaling for suicide and survival. J. Cell. Physiol., 2002, 192(1), 1-15. http://dx.doi.org/10.1002/jcp.10119
297. Lee, H.; Herrmann, A.; Deng, J.H.; Kujawski, M.; Niu, G.; Li, Z.; Forman, S.; Jove, R.; Pardoll, D.M.; Yu, H. Persistently activated Stat3 maintains constitutive NF-jB activity in tumors. Cancer Cell., 2009, 15(4), 283-293. http://dx.doi.org/10.1016/j.ccr.2009.02.015
298. Grivennikov, S.I.; Karin, M. Dangerous liaisons: STAT3 and NF- kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev., 2010, 21(1), 11-19. http://dx.doi.org/10.1016/j.cytogfr.2009.11.005
299. Ak, P.; Levine, A.J. P53 and NF-jB: different strategies for responding to stress lead to a functional antagonism. FASEB J., 2010, 24(10), 3643-3652. http://dx.doi.org/10.1096/fj.10-160549
300. Johnson, R.F.; Witzel, II.; Perkins, N.D. P53-dependent regulation of mitochondrial energy production by the RelA subunit of NF-jB. Cancer Res., 2011, 71(16), 5588-5597. http://dx.doi.org/10.1158/0008-5472.CAN-10-4252
301. Mauro, C.; Leow, S.C.; Anso, E.; Rocha, S.; Thotakura, A.K.; Tornatore, L.; Moretti, M.; De Smaele, E.; Beg, A.A.; Tergaonkar, V.; Chandel, N.S.; Franzoso, G. NF-jB controls energy homeostasis and metabolic adaptation by upregulating mitochondrial respiration. Nat. Cell. Biol., 2011, 13(10), 1272-1279. http://dx.doi.org/10.1038/ncb2324
302. Assaily, W. Benchimol, S. Differential utilization of two ATP-generating pathways is regulated by p53. Cancer Cell., 2006, 10 (1), 4-6. http://dx.doi.org/10.1016/j.ccr.2006.06.014
303. Park, J.Y.; Wang, P.Y.; Matsumoto, T.; Sung, H.J.; Ma, W.; Choi, J.W.; Anderson, S.A.; Leary, S.C.; Balaban, R.S.; Kang, J.G.; Hwang, P.M. P53 improves aerobic exercise capacity and augments skeletal muscle mitochondrial DNA content. Circ. Res., 2009, 105(7), 705-712. http://dx.doi.org/10.1161/CIRCRESAHA.109.205310
304. Saleem, A.; Adhihetty, P.J.; Hood, D.A. Role of p53 in mitochondrial biogenesis and apoptosis in skeletal muscle. Physiol. Genomics., 2009, 37(1), 58-66. http://dx.doi.org/10.1152/physiolgenomics.90346.2008
305. Kawauchi, K.; Araki, K.; Tobiume, K.; Tanaka, N. P53 regulates glucose metabolism through an IKK-NF-kappaB pathway and inhibits cell transformation. Nat. Cell. Biol., 2008, 10(5), 611-618. http://dx.doi.org/10.1038/ncb1724
306. Johnson, R.F.; Perkins, N.D. Nuclear factor-jB, p53, and mitochondria: regulation of cellular metabolism and the Warburg effect. Trends. Biochem. Sci., 2012, 37(8), 317-324. http://dx.doi.org/10.1016/j.tibs.2012.04.002
307. Zhang, C.; Lin, M.; Wu, R.; Wang, X.; Yang, B.; Levine, A.J.; Hu, W.; Feng, Z. Parkin, a p53 target gene, mediates the role of p53 in glucose metabolism and the Warburg effect. PNAS., 2011, 108(39), 16259-16264. http://dx.doi.org/10.1073/pnas.1113884108
308. Morris, G.; Maes, M. Increased nuclear factor-KB and loss of p53 are key mechanisms in Myalgic Encephalomyelitis/chronic fatigue syndrome (ME/CFS). Med. Hypotheses., 2012, 79(5), 607-613. http://dx.doi.org/10.1016/j.mehy.2012.07.034
309. Ma, W.; Sung, H.J.; Park, J.Y.; Matoba, S.; Hwang, P.M. A pivotal role for p53: balancing aerobic respiration and glycolysis. J. Bioenerg. Biomembr., 2007, 39(3), 243-246. http://dx.doi.org/10.1007/s10863-007-9083-0
310. Bensaad, K.; Vousden, K.H. P53: new roles in metabolism. Trends. Cell. Biol, 2007, 17, 286-291. http://dx.doi.org/10.1016/j.tcb.2007.04.004
311. Olovnikov, I.A.; Kravchenko, J.E.; Chumakov, P.M. Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin. Cancer Biol, 2009, 79(1), 32-41. http://dx.doi.org/10.1016/j.semcancer.2008.11.005